Lanwei Medical Stock Price Fluctuates, First Three Quarters Revenue Reaches 1.102 Billion Yuan

MaticHoleFiller · 2026-03-23T19:44:28+00:00

As of March 16, 2026, Lanwei Medical's stock price was 10.52 yuan, showing volatile trading. The Q3 2025 report indicates a decline in main business revenue, with some improvement in net profit. Institutional attention is moderate, with a neutral rating and earnings forecast of 0.76 yuan per share.

MaticHoleFiller

2026-03-23 19:44:28

Abstract generation in progress

Economic Observer Network As of the close on March 16, 2026, Lanswe Medical (301060.SZ) closed at 10.52 yuan, up 0.86% for the day, with a trading volume of 46.81 million yuan; main capital net outflow was 7.7083 million yuan, accounting for 16.47% of total turnover, retail funds net inflow was 2.5936 million yuan, and retail investor net inflow was 5.1147 million yuan. Over the past week (March 11 to 17, 2026), the stock price declined by 2.33%, with a volatility of 3.17%, reaching a high of 10.76 yuan (March 11) and a low of 10.42 yuan (March 13); on March 17, the latest stock price was 10.49 yuan, down 0.29% for the day, with a turnover rate of 0.72% and a trading volume of 27.56 million yuan. Technical analysis shows that the stock has recently been in a consolidation phase, with a resistance level at 11.62 yuan and a support level at 10.03 yuan.

Financial Report Analysis

Lanswe Medical’s Q3 2025 report shows that the main business revenue for the first three quarters was 1.102 billion yuan, down 16.51% year-over-year; net profit attributable to shareholders was -66,770 yuan, an increase of 98.35% year-over-year; in the third quarter alone, revenue was 343 million yuan, down 20.63% year-over-year, but net profit turned profitable to 511,540 yuan. According to institutional forecasts, the full-year net profit for 2025 is expected to be 303 million yuan, a year-over-year increase of 25.21%, with revenue projected at 3.734 billion yuan, up 24.97%. The company’s gross profit margin is 24.19%, and debt ratio is 31.28%.

Institutional Opinions

Institutions’ attention to Lanswe Medical is moderate, with recent public sentiment being neutral. As of March 17, 2026, 0% of ratings are positive, 0% negative, and 100% neutral; only one institution has provided earnings forecasts, estimating EPS of 0.76 yuan for 2025. The frequency of research is low, ranking 73rd out of 504 in the industry.

The above content is compiled from publicly available information and does not constitute investment advice.

Massive information, precise analysis, all on Sina Finance APP

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.